Business Wire

New Calabrio Report, Launched at Customer Event, Diagnoses Why Contact Centers Struggle with High Agent Turnover in 2021

5.10.2021 17:15:00 EEST | Business Wire | Press release

Share

Calabrio, the customer experience intelligence company, today unveiled its latest report, detailing first-hand agent sentiment on the current state of the contact center, the impact that “The Great Resignation” has had on contact centers and the importance of employee-centric practices. The findings were announced on the first day of the annual Calabrio Customer Connect (C3) conference. This year Calabrio’s annual conference, focused on The Connected Workforce, is being held as a virtual event October 5-6, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005256/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Data from Calabrio's agent wellbeing survey uncovers transformational opportunities for the contact center and shows the key importance of employee-centricity. (Photo: Business Wire)

As “The Great Resignation” sweeps across the global labor landscape, many businesses are left both shorthanded and questioning what they could have done to keep their workforce. The study, entitled “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation,” surveyed U.S. and UK contact center agents to uncover transformational opportunities for the contact center from their perspective. Calabrio previously surveyed agents on the same topic in 2017. Whereas the 2017 study was completed before the accelerated shift to remote work, 65% of this study’s respondents were speaking from experience in a hybrid or remote role. This year’s findings reveal that contact centers must prioritize agent retention and engagement or face a dangerous cycle of attrition.

The report found that contact center agents suffer tremendous stress from modern workforce challenges, including rising customer expectations, growing call volume and a shaky work-life balance. According to the study, one-third of agents report feeling acutely stressed multiple times per week. This is an increase from 2017, when just 25% of agents reported that feeling.

Even more importantly, most agents also report that their companies are not doing enough to address agent stress. This agent sentiment has created a never-ending cycle of stress and disengagement, where a third of agents are considering leaving their jobs within one year, and half plan to leave within two or three years.

“Agents are a brand’s only defenders and key ambassadors during this pandemic, and they continue to face one of the most difficult customer service eras in recent memory. Staffing levels are often low while customer expectations are high. Understanding the agent experience is the first step in providing the support they need. This report illustrates that now is the time for contact centers to prioritize the creation of a targeted agent-engagement and retention plan,” said Tom Goodmanson, president and CEO at Calabrio. “As C3 begins, we are excited to share our findings and work together with industry peers and leaders to improve the agent experience, including pushing for a more connected workforce, increased agent flexibility and a greater investment in agent-empowering technologies.”

Other takeaways from the study that tie into the C3 theme of The Connected Workforce include:

  • Money Isn’t Everything: The report found that there is a disconnect between the most asked-for items from agents and their top reasons for leaving. For example, the top ask from agents is more pay, however the top reason for leaving is being unhappy in the job. More money is the number three reason for leaving.
  • Flexibility Isn’t Just About Location: While most agents report that they are now working in their preferred environment, more flexibility is still the second most common agent request.
  • Technology Investments Are Working, But We’re Not There Yet: More agents in this year’s study feel they have the correct technology to handle challenges compared to the 2017 study, but “lack of tools” and “lack of data” are still the top two reasons agents report for why they fail to solve customer issues.

For a full report of the data and findings go to “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation.”

About Calabrio Customer Connect: October 5-6, 2021

Attend Calabrio Customer Connect (C3) to learn more about the importance of employee-centric practices and to hear from contact center peers on specific ideas for retaining staff. The annual event brings together the global contact center industry for education and networking and features more than 50 breakout sessions and keynotes from industry leaders. This year, the virtual event will feature multiple tracks to accommodate different attendees, such as the Workforce Connection, Performance Connection, Complete Connection, Partner Connection and the Connected Enterprise. To register and view this year’s breakout sessions, visit: https://www.calabriocustomerconnect.com/breakout-sessions/.

About Calabrio

Calabrio is the customer experience intelligence company that empowers organizations to enrich human interactions. The scalability of our cloud platform allows for quick deployment of remote work models—and it gives our customers precise control over both operating costs and customer satisfaction levels. Our AI-driven analytics tools make it easy for contact centers to uncover customer sentiment and share compelling insights with other parts of the organization. Customers choose Calabrio because we understand their needs and provide a best-in-class experience, from implementation to ongoing support. Find more at calabrio.com and follow @Calabrio on Twitter.

Calabrio, Calabrio ONE® and the Calabrio logo are registered trademarks or trademarks of Calabrio, Inc. All other trademarks mentioned in this document are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Amy Fisher
612.455.1773
CalabrioPR@padillaco.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release

The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release

Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye